Beta Bionics (NASDAQ:BBNX – Get Free Report) and RenovoRx (NASDAQ:RNXT – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.
Analyst Ratings
This is a breakdown of current ratings for Beta Bionics and RenovoRx, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beta Bionics | 1 | 4 | 9 | 1 | 2.67 |
| RenovoRx | 1 | 0 | 2 | 1 | 2.75 |
Beta Bionics presently has a consensus price target of $23.69, suggesting a potential upside of 45.20%. RenovoRx has a consensus price target of $8.50, suggesting a potential upside of 543.94%. Given RenovoRx’s stronger consensus rating and higher probable upside, analysts clearly believe RenovoRx is more favorable than Beta Bionics.
Insider & Institutional Ownership
3.1% of RenovoRx shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by insiders. Comparatively, 9.4% of RenovoRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
Beta Bionics has a beta of 3.44, meaning that its share price is 244% more volatile than the S&P 500. Comparatively, RenovoRx has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.
Profitability
This table compares Beta Bionics and RenovoRx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beta Bionics | -65.31% | -27.33% | -24.28% |
| RenovoRx | -621.71% | -135.11% | -101.91% |
Valuation and Earnings
This table compares Beta Bionics and RenovoRx”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beta Bionics | $100.25 million | 8.85 | -$73.20 million | ($1.84) | -8.87 |
| RenovoRx | $1.12 million | 53.19 | -$11.17 million | ($0.31) | -4.26 |
RenovoRx has lower revenue, but higher earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than RenovoRx, indicating that it is currently the more affordable of the two stocks.
Summary
RenovoRx beats Beta Bionics on 8 of the 14 factors compared between the two stocks.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
About RenovoRx
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
